Status Awaiting development
Process TAG
ID number 4014

Provisional Schedule

Expected publication 01 February 2023


Key events during the development of the guidance:

Date Update
26 November 2021 Following a request received from the company, NICE will be undertaking an appraisal of Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma. This was originally terminated guidance TA634. The appraisal is expected to start during January 2022 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during mid-March 2022. The deadline for submissions is expected in approximately late May 2022.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance